Farringdon Capital’s BeOne Medicines Ltd ONC Stock Holding History

Farringdon Capital’s Portfolio ONC Stock Details ONC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-1,018	Closed	-$246K	–	685
2025 Q2	$246K	Buy	+1,018	New	+$250K	0.08%	366

Other funds holding ONC

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return

Temasek Holdings Singapore $30.5B AUM 13.98% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Farringdon Capital's ONC Position: Q3 2025 in Review

Farringdon Capital sold out of BeOne Medicines Ltd (ONC) in Q3 2025, closing a stake of 1,018 shares — an estimated $246K sold.

Farringdon Capital first reported a position in ONC in Q2 2025 and held it in 1 quarter. The position peaked at $246K in Q2 2025. 265 funds tracked by Wall St. Rank hold ONC as of Q3 2025.

Farringdon Capital reported no remaining BeOne Medicines Ltd position as of Q3 2025 after selling out during the quarter.
Farringdon Capital sold 1,018 BeOne Medicines Ltd shares in Q3 2025, an estimated $246K.
Farringdon Capital first reported a position in BeOne Medicines Ltd in Q2 2025 and held it in 1 quarter.
Farringdon Capital's BeOne Medicines Ltd position peaked at $246K in Q2 2025.
265 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q3 2025.

Based on Farringdon Capital's 13F filing for Q3 2025, filed 13 Nov 2025.